The Wegovy shot is a once-weekly subcutaneous injection of semaglutide 2.4 mg, approved by the FDA for chronic weight management in eligible adults and adolescents. It belongs to the GLP-1 receptor agonist class and works by reducing appetite, slowing gastric emptying, and influencing reward pathways linked to food intake.
What the Wegovy Shot Contains
Wegovy is semaglutide, the same active ingredient in Ozempic, but at a higher maximum weekly dose specifically studied for weight management. It is delivered through a prefilled single-dose pen placed subcutaneously in the abdomen, thigh, or upper arm. According to FDA prescribing information, the shot should be rotated between injection sites each week.
How the Wegovy Shot Works
Semaglutide mimics the incretin hormone GLP-1. By binding GLP-1 receptors, it:
- Slows gastric emptying, prolonging fullness after meals
- Reduces appetite signals in the hypothalamus
- Lowers postmeal blood sugar by enhancing insulin release and suppressing glucagon
- Modulates food reward circuits that drive cravings
These combined effects support sustained caloric deficit without the hunger rebound that often limits diet-only approaches. For a broader view of metabolic medication options, see our treatment hub.
Benefits in Clinical Trials
The STEP 1 trial, published in the New England Journal of Medicine, reported average weight loss of about 14.9 percent at 68 weeks among adults with obesity without diabetes, compared with 2.4 percent in the placebo group. Approximately one-third of participants lost 20 percent or more of their starting weight. The later SELECT cardiovascular outcomes trial, also in NEJM, found Wegovy reduced major adverse cardiovascular events in high-risk adults with established cardiovascular disease and obesity.
Typical Titration Schedule
The Wegovy shot is titrated to minimize gastrointestinal side effects before reaching the maintenance dose of 2.4 mg weekly.
| Month | Dose (mg weekly) | Purpose |
|---|---|---|
| 1 | 0.25 | Tolerance introduction |
| 2 | 0.5 | Continued titration |
| 3 | 1.0 | Continued titration |
| 4 | 1.7 | Pre-maintenance |
| 5+ | 2.4 | Maintenance dose |
Side Effects
Gastrointestinal effects are the most common reason people discontinue. Nausea, diarrhea, constipation, vomiting, and abdominal pain are reported in a significant minority of users. These typically improve after several weeks at a stable dose. Less common but more serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, and hypoglycemia when combined with insulin or sulfonylureas. The drug carries a boxed warning about thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Who Should Avoid the Wegovy Shot
Contraindications include known hypersensitivity, personal or family history of medullary thyroid carcinoma, MEN 2, and pregnancy. Caution is advised in people with pancreatitis history, gallbladder disease, severe gastrointestinal disease, or active diabetic retinopathy. The American Diabetes Association recommends individualized decision-making for any GLP-1 therapy based on comorbidities.
Lifestyle Still Matters
Wegovy is most effective alongside nutrition changes and physical activity. Reduced appetite makes caloric deficits easier to sustain, but nutrient quality, protein intake, and resistance exercise help protect lean body mass during weight loss. If you are earlier in the metabolic spectrum, our prediabetes reversibility guide and diet and nutrition hub offer foundational lifestyle strategies.
Practical Notes on Using the Shot
The pen is designed for self-injection after brief training from a clinician or pharmacist. Typical practical steps include rotating injection sites weekly, avoiding areas with bruising or scarring, and storing unused pens in the refrigerator. Specific technique should be learned directly from the prescribing team because details vary by pen design and by individual factors.
The Bottom Line
The Wegovy shot is an effective, evidence-backed option for chronic weight management in adults and eligible adolescents, with trial data showing significant weight loss and, in the SELECT trial, cardiovascular benefit. It is not a quick fix and carries real risks that require clinician oversight. If you are considering the Wegovy shot, speak with a qualified provider who can evaluate your eligibility, monitor your response, and coordinate it with other parts of your care.
Medical disclaimer: This content is educational and does not replace personalized medical advice. Always consult a licensed clinician before starting or stopping any prescription medication.
